Major targets are members of the erbB family of growth factor receptors, principally EGFR and HER2, which are known to play important roles in breast cancer pathogenesis (Lacroix et al, 1989; Slamon et al, 1990; Klijn et al, 1992). Here, ERBB2 is linked to breast carcinoma.